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Introduction 
Researchers and clinicians have long recognized that understanding patient perceptions of their 
health provides a fuller appreciation of the range of symptoms and life impact of chronic conditions. Yet, 
until recently it was also believed that the responsibility for defining outcomes and creating measures 
rested largely with health professionals. Beginning in the late 1970’s, select groups began to 
acknowledging that beyond serving solely as research subjects, patients had an important view to 
consider. However, the idea that patients could offer valuable input as research partners only gained 
traction when people with HIV/AIDs began insisting that they had a right to help identify research priorities 
and outcomes (1). By the millennium, several scientific organisations (e.g., Outcome Measures in 
Rheumatology -- OMERACT) championed the necessity of always involving people living with health 
conditions as collaborative research partners.  
Fifteen years later, much has been accomplished and several approaches have emerged as a 
growing number of researchers and organizations seek to improve research by directly engaging patients. 
Within ISPOR, the Patient-Centered Special Interest Group (SIG) began in 2013 and the Patient 
Engagement in Research Work Group began in 2014.  Similarly, within the International Society of 
Quality of Life Research (ISOQOL), a Patient Engagement SIG was formed in 2012. However, despite 
growing interest, evidence for the impact of patient engagement on outcomes research, measurement 
development, and healthcare decision-making is limited (2-6). Further, little guidance is available for 
approaches that work well, for whom, and in what context (7).  
To further understanding of how to integrate patients into all aspects of outcomes research, 
including PRO development, we describe and discuss the experiences of three patient-centered 
outcomes research (PCOR) stakeholders: a clinical research leader, a patient research partner (PRP), 
and a representative of a PCOR funder. These real-world examples illustrate different approaches and 
levels of PRP integration, the added value PRPs contribute to outcomes research, and highlight lessons 
learned to optimize engagement. Although each organization represented has created organization-
specific principles and recommendations for engagement, a set of basic guidelines for optimizing success 
of research partnerships, generalizable to outcomes research, emerges across the groups.  
*Blinded Manuscript [no author details]
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A Researcher’s Experience 
Professor John Kirwan (Consultant Rheumatologist, Bristol UK), an experienced clinical 
researcher working to improve the lives of people with rheumatic diseases, has integrated patients into 
the international research organization OMERACT. He was responsible for guiding and implementing the 
current policy in OMERACT that states outcome measures can only be adopted if patients have 
participated in their development (8, 9). 
OMERACT is an independent initiative of international health professionals which uses a data- 
driven, multi-stakeholder consensus process to identify and improve outcome measures in 
musculoskeletal conditions (10). Since 1990, OMERACT has served a critical role developing and 
validating rheumatology outcome measures. Evidence supporting existing PROs as primary outcomes or 
the need to develop new PROs is presented at biennial meetings. There is detailed small group 
discussion followed by plenary summaries. All participants, including the PRPs are involved in decision-
making through real-time electronic voting to determine whether proposed measures are endorsed by 
OMERACT.  
Currently, patients are integrated into all stages of the OMERACT process as the personal 
experiential knowledge living with their condition adds to the theoretical and empirical knowledge of 
researchers and clinicians. However, direct patient engagement only started in 2000 at OMERACT 5; as 
deliberations were being held to gain consensus on clinically important change in existing measures in 
rheumatoid arthritis (RA), Dr. Kirwan aptly noted that patients also might have a view on this. This spurred 
discussion on how patients could potentially contribute more widely to the development and selection of 
outcomes in clinical trials, and OMERACT resolved to include patients at the 2002 meeting. From 2000 
through 2012, Dr. Kirwan was responsible for coordinating patients’ input into the OMERACT process and 
meetings. By 2016, patients were fully incorporated into all activities (Figure 1).  
<Figure 1> 
As experience with patient engagement accumulated, the benefits were more widely appreciated, 
valued, and patients were incorporated into all activities (8). Today, all OMERACT working groups include 
PRPs as they undertake research between biennial meetings; groups presenting during plenaries must 
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fund at least one PRP to attend. At meetings, patients have full voting rights and participate in all 
sessions. Attendance at several meetings has allowed some patients to become very familiar with the 
process, and they now occupy a ‘halfway house’ between researchers and patients. Patients continue to 
provide their experience-based perspective, a perspective researchers do not have; PRPs involved over 
time are able to understand more, and are more comfortable with the language of, and constraints 
imposed by, the research process. Indeed, one PRP (MdW) undertook doctoral studies and became a 
researcher in his own right. 
These changes have had a large impact. Researchers already committed to doing the best for 
their patients, recognize the benefits of including patients when conceiving, designing, carrying out 
research and disseminating results (11). Perhaps the most dramatic consequence has been the 
refocusing of the research community on fatigue in RA. Initially, fatigue was omitted from the 1992 core 
outcome set. PRPs highlighted how fatigue affects everyday life, stimulating research to quantify its 
impact and demonstrate how fatigue assessment adds understanding of trial outcomes. As a result, 
OMERACT now endorses fatigue as a necessary assessment in all future RA trials (12-14).  
By 2016, the involvement of PRPs (about 10% of conference participants) is now so pervasive 
that it is difficult to separate their contribution from those of researchers and other stakeholders. However, 
achieving this required a sustained effort by organisers to ensure patient involvement over successive 
meetings. Important lessons have been learned. A commitment to funding PRP participation in working 
groups and conference attendance was an early step, as was increasing the educational support and 
training given to patients at conferences. For example, each day, organizers of the next day’s sessions 
meet with PRPs to explain how they came to be on the program, what they hope to achieve, what 
patients should look for, and how they might best contribute to small group discussions. This is an 
example of the type of research training that can benefit partnerships by ensuring that patients 
understand the research agenda and goals and can feel comfortable in the discussions while recognizing 
the unique perspective they bring.   
Within OMERACT, PRPs organize training to prepare new PRPs and update experienced ones. 
At OMERACT 2016, experienced PRPs held an introductory webinar and half-day session for new 
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participants immediately before the meeting. They provided a glossary explaining terms such as RCT and 
validity. (The glossary has proven so popular that all attendees now receive a copy.) Lay summaries of 
each session are included in the program.  
Over 16 years, PRPs and researchers have learned new skills and OMERACT has published 
recommendations for meaningfully engaging PRPs in all working groups (15). The OMERACT experience 
highlights the importance of education and training to support successful partnerships, and how attitudes, 
of researchers, PRPs, and organizations create a culture in which partnerships can thrive. 
 
A PRP’s Experience 
Maarten de Wit lives with psoriatic arthritis (PsA), and is a PRP. He worked with the European 
League Against Rheumatism (EULAR) to create recommendations for patient engagement in scientific 
projects (16) which helped guide development of a new measure in PsA. Because there was no existing 
measure reflecting the patient perspective (17, 18), EULAR facilitated the development and validation of 
the Psoriatic Arthritis Impact of Disease score (PsAID) (19). PsAID developers now use this work as a 
case study of a successful patient-research partnership in developing a new outcome measure (20).   
This project serves as a best practice exemplar because it demonstrates multiple forms of PRP 
participation throughout PRO development. Different PRPs were involved in subsequent phases, 
contributing in diverse ways, and at all levels. This example also demonstrates the role of research team 
attitudes in creating an environment that supports partnership. Below is a summary of the range of 
activities that PRPs undertook.  
Steering committee. Two PRPs were part of the steering group, participating in all discussions 
and decision-making.  
Foundational qualitative work. Initially, PRPs from 11 European countries participated in a 
meeting (led by a nurse researcher and patient) to identify life impact domains accordance with EULAR 
recommendations (Table 1) (16). PRPs were recruited through the clinics of participating physician-
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researchers to identify those who could travel, had relevant skills, and were interested in collaborating on 
this project.  
Questionnaire development, refinement, and validation. 139 patients prioritized 16 life-impact 
domains, and 65 patients provided feedback on item wording, and offered alternative terms when 
translating the questionnaire into different languages (21). Initial validation included 499 new patients 
from 11 countries who completed questionnaires and underwent a clinical examination.  
While there was agreement on many things, there was also some discordance. For example, 
patients strongly favored including coping questions as this was viewed as an important indicator of 
poorly-controlled disease. There was debate about three items that queried embarrassment/shame, 
social participation, and depression. Many of the professionals and some patients questioned the added 
value of asking all patients in a clinical trial about the psychosocial consequences of PsA; others argued 
that they were important for some, and should be part of patient-physician conversations. Given that the 
the initial objective was to develop a tool appropriate for both clinical trials and practice, the team 
developed two versions: a 9-item PsAID focusing on measurement objectives to meet the needs of 
trialists, and a 12-item version for clinical practice as many patients want the psychological impact of 
living with PsA to be part of broader conversations. Most researchers agreed that involving patients was 
essential when developing PROs. 
Evidence from EULAR and others suggests that the investigators play a key role in successfully 
integrating PRPs into projects and eliciting meaningful contributions (22-24). As with OMERACT, EULAR 
PRPs received education and support to better understand the research process, fully participate in 
meetings, and confidently voice opinions, while still providing their unique experience-based perspective. 
PRPs sessions were held before team meetings. A glossary helped them learn about research (e.g., the 
experimental method). Project-specific education included: 1) Explaining the goals and process of PRO 
development; 2) providing basic information on how PROs are validated and why this is 
important. Newsletters kept all team members informed of progress. PRPs helped draft the manuscript as 
co-authors (25).  
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Thus, PsAID development demonstrates that PRPs and researchers can successfully collaborate 
to develop new patient-centered instruments for research and clinical settings. This examples illustrates 
how training enabled patients to participate fully in meetings, how patient involvement strengthened the 
measures that emerged, and how attitudes of trust, respect, co-learning, and reciprocity facilitated the 
partnership. 
A Funder’s Experience 
PCORI (The Patient Centered Outcomes Research Institute) is a non-profit, nongovernmental 
organization that funds patient-centered clinical comparative effectiveness research. PCOR is defined as 
the “evaluation of questions and outcomes meaningful and important to patients and caregivers” (26). 
PCORI requires stakeholder engagement in all its funded research, defining stakeholders as any end-
user of the research, including (but not limited to) patients, caregivers, clinicians, hospital administrators, 
healthcare policymakers, industry researchers, and drug and device manufacturers.  
To meet PCORI research engagement requirements, awardees must demonstrate that patients 
or other relevant end-users are included in the production of research evidence, beyond serving as 
subjects. Engagement can take many forms. Advisory panels, generally implemented as meetings 
between researchers and intended end-users, are a common model of engagement among PCORI 
awardees. In practice, PRPs engage with researchers in diverse ways, from serving as consultants on 
select portions of the project to co-investigators signifying influence on and responsibility for the work on 
par with researchers. PCORI encourages partnership across different stages of research (e.g., 
determining study questions, study design, implementation, dissemination) as appropriate 
(http://www.pcori.org/sites/default/files/Engagement-Rubric.pdf).  
Conceptual model of PCOR. To guide applicants and researchers, PCORI and others created a 
conceptual model of PCOR, based on relevant literature and consultation with the PCORI Patient 
Engagement Advisory Panel (27). This conceptual model can serve as the basis for measurement 
models to test relationships between elements in the model (Figure 2), along with a companion evaluative 
framework for research engagement (28).  
<Figure 2> 
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The model identifies foundational elements for PCOR, including channels for communication, 
resources and infrastructure, and organizational policies, each supporting the research partnership. 
Action elements are the behaviors that researchers and partners engage in to permit successful PCOR. 
Communication is key, as is active solicitation of patient perspectives throughout the research process, 
and sharing of results with end-users. The ultimate goal of PCOR is optimized health outcomes.  
Learning about engagement in research from PCORI awardees. To identify best practices in 
research engagement and to develop descriptive information from which elements of the conceptual 
model can be evaluated, PCORI has collected information from awardees focused on engagement with 
research partners or other end-users. Early data identified time as a challenge for both researchers and 
partners (29). Nevertheless, establishing and maintaining relationships between researchers and end-
users requires time. For many researchers, factoring in time to meet with research partners is a new 
practice but it is notable that many awardees see the value of restructuring team activities to allow for 
time with research partners. Doing so has altered the research: questions and study designs have been 
changed, as have ways in which participants are recruited and information is shared with patient 
communities (29). These findings are consistent with OMERACT and EULAR experiences, pointing to the 
resources required to establish and maintain research partnerships, including familiarizing PRPs with 
relevant terminology and research processes to optimize their contributions. 
 PCORI’s goal is to help people make informed health care decisions through funding research 
guided by patients, caregivers and the broader health care community. Guidelines for applicants about 
research partnerships, such as the PCORI Engagement Rubric and the Methodology Standards, echo 
elements from OMERACT and EULAR.  Training of patients and researchers is recommended with 
recognition of the different resource requirements required to establish and maintain research 
partnerships. Principles of trust, co-learning, reciprocity in relationships and respect emerge from 
awardees as important elements. Attitudes toward engagement, along with institutional policies, are 
important for establishing a foundation in which research engagement can proceed.  
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Discussion  
 These examples from different stakeholders converge on several points, from which guidelines 
for engagement in outcomes research can be distilled. PRPs represent the voices and needs of patients 
and enhance all phases of research. Across different models presented, similar principles to guide 
integration of PRPs engagement in research have emerged that include:  
1. Establishing supportive institutional policies; 
2. Fostering supportive attitudes, with understanding that optimal partnerships evolve over time and 
are grounded in strong communication and shared goals;  
3. Adhering to principles of respect, trust, reciprocity, and co-learning; 
4. Addressing training needs of all team members to ensure productive communication and that 
PRPs are familiar with the language and process of research;  
5. Identifying and providing the resources and advanced planning required for successful patient 
engagement;  
6. Recognizing the value that research partnerships bring across all stages of research, from 
research conceptualization through dissemination of findings. 
While similarities appear across examples, each project is unique, necessitating clear 
communication about expectations of all members. More research is needed to identify the skills and 
qualities that contribute to successful research partnerships in terms of individual and collective needs, 
values, and required resources. Further work also is needed to develop insights and best practices for 
training of researchers and patients to work well together in designing new measures and implementing 
outcomes research. Consensus-driven guidelines for reporting patient engagement are available 
(GRIPP2) (30) highlighting the importance of detailing the context (support; training; funding and time); 
processes adopted (methods adopted; levels of engagement; stages of the research during which 
patients were involved as research partners); and outcomes. Careful documentation of these aspects can 
contribute to the development of a knowledge-base for engaged research.  
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 Challenges in patient-research partnerships. PRPs should possess a set of core 
competencies that align with the project’s objectives and process but considerable uncertainty remains 
around identifying these. The reality of limited time must be faced, as time spent identifying and 
developing productive relationships with PRPs too often represents “unfunded activities.” OMERACT 
allocated funds and personnel to support patient engagement from the initiation of working groups.  As a 
funder, PCORI recognizes that meaningful engagement of patients in research may add time and costs to 
research projects, and application reviewers are made aware of the different resources and needs that 
this type of research can produce, relative to non-engaged research models. The cultural impact of PRPs 
also warrants evaluation, including attention to positive and negative consequences for researchers and 
PRPs. 
 
Conclusions 
We have described three ways that outcomes research was improved by involving PRPs. 
Supporting patients in their role as full research partners enables them to contribute their experiential 
knowledge and help ensure results are relevant and address patient needs, preferences and priorities.  
Organisations such as ISPOR, ISOQOL, OMERACT, EULAR, PCORI and others recognise the 
benefits and mandate that patient partners are incorporated into their structure and function. Within 
ISPOR, the Patient-centered SIG is poised to facilitate this 
(http://www.ispor.org/sigs/patientcentered/pc_engagementinresearch.aspx). As PCOR spreads to other 
organizations, it will be important to collect evidence on the impact of engaging PRPs in research and to 
identify ways to facilitate it across disciplines. While views about the value of patient engagement are not 
based on controlled trials (e.g., comparing engagement vs no engagement), recognizing the value of 
patient engagement can both reflect and drive the cultural shift among researchers. 
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Figure 1. Evolution of patient involvement in OMERACT (Outcome Measures in 
Rheumatology) activities and organization. [2016 planned as at  23 March 2016] 
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Figure 2. Conceptual model of patient-centered outcomes research. From Frank et al., Qual Life Res, 
2015 (23). 
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Table 1. European League Against Rheumatism recommendations for the inclusion of patient 
representatives in scientific projects.  
1. Participation of patient research partners is strongly recommended for clinical research projects and for 
the development of recommendations and guidelines, and should be considered for all other research 
projects. 
2. Participation of patient research partners should be considered in all phases of the project to provide 
experiential knowledge, with the aim of improving the relevance, quality and validity of the research 
process. 
3. A minimum of two patient research partners should be involved in each project.  
4. Identification of potential patient research partners should be supported by a clear description of 
expected contributions. 
5. The selection process of patient research partners should take into account communication skills, 
motivation and constructive assertiveness in a team setting. 
6. The principal investigator must facilitate and encourage the contribution of patient research partners, 
and consider their specific needs. 
7. The principal investigator must ensure that patient research partners receive information and training 
appropriate to their roles. 
8. The contribution of patient research partners to projects should be appropriately recognised, including 
coauthorship when eligible. 
Adapted with permission from de Wit et al., Annals of Rheumatic Diseases, 2011, doi: 
10.1136/ard.2010.135129  
Table 1
